vs
AVANOS MEDICAL, INC.（AVNS）与Revolve Group, Inc.（RVLV）财务数据对比。点击上方公司名可切换其他公司
Revolve Group, Inc.的季度营收约是AVANOS MEDICAL, INC.的1.8倍（$324.4M vs $180.9M），Revolve Group, Inc.净利率更高（5.7% vs -0.7%，领先6.4%），Revolve Group, Inc.同比增速更快（10.4% vs 0.7%），AVANOS MEDICAL, INC.自由现金流更多（$21.3M vs $-13.3M），过去两年Revolve Group, Inc.的营收复合增速更高（9.5% vs 4.4%）
Avanos Medical是一家医疗科技企业，专注于研发生产临床医疗设备，核心业务围绕疼痛管理与慢性护理两大板块展开，致力于帮助患者加快康复、预防感染，同时减少临床治疗中阿片类药物的使用。
Revolve Theatre Company是总部位于英国泰晤士河畔亨利的剧团，专注于创作演出政治题材和莎士比亚系列戏剧作品，由奥利弗·登奇、乔·莫里斯与汤姆·史密斯共同创立运营。
AVNS vs RVLV — 直观对比
营收规模更大
RVLV
是对方的1.8倍
$180.9M
营收增速更快
RVLV
高出9.7%
0.7%
净利率更高
RVLV
高出6.4%
-0.7%
自由现金流更多
AVNS
多$34.6M
$-13.3M
两年增速更快
RVLV
近两年复合增速
4.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $180.9M | $324.4M |
| 净利润 | $-1.3M | $18.6M |
| 毛利率 | 47.5% | 53.3% |
| 营业利润率 | 1.4% | 6.3% |
| 净利率 | -0.7% | 5.7% |
| 营收同比 | 0.7% | 10.4% |
| 净利润同比 | 99.7% | 50.4% |
| 每股收益（稀释后） | $-0.02 | $0.27 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AVNSRVLV
| Q4 25 | $180.9M | $324.4M | ||
| Q3 25 | $177.8M | $295.6M | ||
| Q2 25 | $175.0M | $309.0M | ||
| Q1 25 | $167.5M | $296.7M | ||
| Q4 24 | $179.6M | $293.7M | ||
| Q3 24 | $170.4M | $283.1M | ||
| Q2 24 | $171.7M | $282.5M | ||
| Q1 24 | $166.1M | $270.6M |
净利润AVNSRVLV
| Q4 25 | $-1.3M | $18.6M | ||
| Q3 25 | $-1.4M | $21.2M | ||
| Q2 25 | $-76.8M | $10.2M | ||
| Q1 25 | $6.6M | $11.8M | ||
| Q4 24 | $-397.3M | $12.3M | ||
| Q3 24 | $4.3M | $11.0M | ||
| Q2 24 | $1.8M | $15.4M | ||
| Q1 24 | $-900.0K | $10.9M |
毛利率AVNSRVLV
| Q4 25 | 47.5% | 53.3% | ||
| Q3 25 | 48.4% | 54.6% | ||
| Q2 25 | 52.6% | 54.1% | ||
| Q1 25 | 53.6% | 52.0% | ||
| Q4 24 | 54.6% | 52.5% | ||
| Q3 24 | 54.5% | 51.2% | ||
| Q2 24 | 55.7% | 54.0% | ||
| Q1 24 | 57.1% | 52.3% |
营业利润率AVNSRVLV
| Q4 25 | 1.4% | 6.3% | ||
| Q3 25 | 0.1% | 7.1% | ||
| Q2 25 | -42.6% | 5.8% | ||
| Q1 25 | 6.1% | 5.0% | ||
| Q4 24 | -233.0% | 3.9% | ||
| Q3 24 | 7.0% | 5.0% | ||
| Q2 24 | 3.7% | 5.8% | ||
| Q1 24 | 2.4% | 3.4% |
净利率AVNSRVLV
| Q4 25 | -0.7% | 5.7% | ||
| Q3 25 | -0.8% | 7.2% | ||
| Q2 25 | -43.9% | 3.3% | ||
| Q1 25 | 3.9% | 4.0% | ||
| Q4 24 | -221.2% | 4.2% | ||
| Q3 24 | 2.5% | 3.9% | ||
| Q2 24 | 1.0% | 5.4% | ||
| Q1 24 | -0.5% | 4.0% |
每股收益（稀释后）AVNSRVLV
| Q4 25 | $-0.02 | $0.27 | ||
| Q3 25 | $-0.03 | $0.29 | ||
| Q2 25 | $-1.66 | $0.14 | ||
| Q1 25 | $0.14 | $0.16 | ||
| Q4 24 | $-8.64 | $0.18 | ||
| Q3 24 | $0.09 | $0.15 | ||
| Q2 24 | $0.04 | $0.21 | ||
| Q1 24 | $-0.02 | $0.15 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $89.8M | $292.3M |
| 总债务越低越好 | $90.3M | — |
| 股东权益账面价值 | $778.2M | $512.5M |
| 总资产 | $1.1B | $765.0M |
| 负债/权益比越低杠杆越低 | 0.12× | — |
8季度趋势，按日历期对齐
现金及短期投资AVNSRVLV
| Q4 25 | $89.8M | $292.3M | ||
| Q3 25 | $70.5M | $315.4M | ||
| Q2 25 | $90.3M | $310.7M | ||
| Q1 25 | $97.0M | $300.8M | ||
| Q4 24 | $107.7M | $256.6M | ||
| Q3 24 | $89.0M | $252.8M | ||
| Q2 24 | $92.2M | $244.7M | ||
| Q1 24 | $75.8M | $273.4M |
总债务AVNSRVLV
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
股东权益AVNSRVLV
| Q4 25 | $778.2M | $512.5M | ||
| Q3 25 | $778.0M | $490.2M | ||
| Q2 25 | $776.3M | $468.6M | ||
| Q1 25 | $839.4M | $453.4M | ||
| Q4 24 | $828.5M | $437.8M | ||
| Q3 24 | $1.2B | $420.8M | ||
| Q2 24 | $1.2B | $405.8M | ||
| Q1 24 | $1.2B | $389.9M |
总资产AVNSRVLV
| Q4 25 | $1.1B | $765.0M | ||
| Q3 25 | $1.1B | $751.3M | ||
| Q2 25 | $1.0B | $722.9M | ||
| Q1 25 | $1.1B | $713.9M | ||
| Q4 24 | $1.2B | $665.5M | ||
| Q3 24 | $1.7B | $670.9M | ||
| Q2 24 | $1.7B | $657.8M | ||
| Q1 24 | $1.7B | $650.0M |
负债/权益比AVNSRVLV
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.2M | $-10.2M |
| 自由现金流经营现金流 - 资本支出 | $21.3M | $-13.3M |
| 自由现金流率自由现金流/营收 | 11.8% | -4.1% |
| 资本支出强度资本支出/营收 | 3.8% | 1.0% |
| 现金转化率经营现金流/净利润 | — | -0.55× |
| 过去12个月自由现金流最近4个季度 | $43.1M | $48.0M |
8季度趋势，按日历期对齐
经营现金流AVNSRVLV
| Q4 25 | $28.2M | $-10.2M | ||
| Q3 25 | $14.0M | $11.8M | ||
| Q2 25 | $6.8M | $12.6M | ||
| Q1 25 | $25.7M | $45.1M | ||
| Q4 24 | $57.9M | $3.9M | ||
| Q3 24 | $23.0M | $9.1M | ||
| Q2 24 | $27.8M | $-24.7M | ||
| Q1 24 | $-8.0M | $38.4M |
自由现金流AVNSRVLV
| Q4 25 | $21.3M | $-13.3M | ||
| Q3 25 | $7.0M | $7.5M | ||
| Q2 25 | $-4.2M | $10.4M | ||
| Q1 25 | $19.0M | $43.4M | ||
| Q4 24 | $53.1M | $2.1M | ||
| Q3 24 | $20.0M | $8.0M | ||
| Q2 24 | $21.9M | $-25.7M | ||
| Q1 24 | $-12.1M | $36.7M |
自由现金流率AVNSRVLV
| Q4 25 | 11.8% | -4.1% | ||
| Q3 25 | 3.9% | 2.5% | ||
| Q2 25 | -2.4% | 3.4% | ||
| Q1 25 | 11.3% | 14.6% | ||
| Q4 24 | 29.6% | 0.7% | ||
| Q3 24 | 11.7% | 2.8% | ||
| Q2 24 | 12.8% | -9.1% | ||
| Q1 24 | -7.3% | 13.5% |
资本支出强度AVNSRVLV
| Q4 25 | 3.8% | 1.0% | ||
| Q3 25 | 3.9% | 1.5% | ||
| Q2 25 | 6.3% | 0.7% | ||
| Q1 25 | 4.0% | 0.6% | ||
| Q4 24 | 2.7% | 0.6% | ||
| Q3 24 | 1.8% | 0.4% | ||
| Q2 24 | 3.4% | 0.4% | ||
| Q1 24 | 2.5% | 0.6% |
现金转化率AVNSRVLV
| Q4 25 | — | -0.55× | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | 1.24× | ||
| Q1 25 | 3.89× | 3.82× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | 5.35× | 0.83× | ||
| Q2 24 | 15.44× | -1.60× | ||
| Q1 24 | — | 3.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
RVLV
| Fashion Apparel | $155.1M | 48% |
| Dresses | $76.4M | 24% |
| Handbags Shoes And Accessories | $67.6M | 21% |
| Beauty | $20.3M | 6% |
| Manufactured Product Other | $5.0M | 2% |
| Breakage On Store Credit And Gift Cards | $900.0K | 0% |
